Drug-induced erythema nodosum after the administration of certolizumab in Crohn's disease

Inflammatory Bowel Diseases

Volumn 19, Issue 1, 2013, Pages

  Biedermann, L ^a   Kerl, K ^b   Rogler, G ^a   Hofbauer, G F L ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; STEROID;

ADULT; CASE REPORT; CROHN DISEASE; DEEP VEIN THROMBOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DOPPLER ECHOGRAPHY; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; FEMALE; GIANT CELL; HISTIOCYTE; HUMAN; INFLAMMATORY CELL; LETTER; LYMPHOCYTE; MULTINUCLEAR CELL; PANNICULITIS; PRIORITY JOURNAL; SKIN DEFECT; SKIN TUBERCULOSIS; SUBCUTANEOUS NODULE; SWITZERLAND; THROMBOPHLEBITIS; UNITED STATES;

ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; ERYTHEMA NODOSUM; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROGNOSIS;

EID: 84873622497     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21942     Document Type: Letter

References (8)

1. Requena L, Requena C. Erythema nodosum. Dermatol Online J. 2002;8:4.
2. Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. Clin Dermatol. 2010;26: 265-273.
3. Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116-1122.
4. Yüksel I, Başar O, Ataseven H, et al. Mucocutaneous manifestations in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:546-550.
5. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. Dig Dis Sci. 1993;38:1137-1146.
6. Basler RS. Ulcerative colitis and the skin. Med Clin North Am. 1980;64:941-954.
7. White JW. Erythema nodosum. Dermatol Clin. 1985; 3:119-127.
8. Hyrich KL, Lunt M, Watson KD, et al. British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56:13-20.